Fluidigm 代理

详细介绍

产品咨询

世界*实验材料供应商 Fluidigm  正式上海金畔为其中国代理， Fluidigm  在一直是行业的*,一直为广大科研客户提供zui为优质的产品和服务,上海金畔一直秉承为中国科研客户带来的产品，的服务， Fluidigm  就是为了给广大科研客户带来更加完善的产品和服务,您的满意将是我们zui大的收获

 Fluidigm  中国代理, Fluidigm  上海代理， Fluidigm  北京代理，Fluidigm  广东代理， Fluidigm  江苏代理Fluidigm  湖北代理,Fluidigm  天津,Fluidigm  黑龙江代理,Fluidigm  内蒙古代理,Fluidigm  吉林代理,Fluidigm  福建代理, Fluidigm  江苏代理, Fluidigm  浙江代理, Fluidigm  四川代理,

Fluidigm creates and manufactures innovative technologies and life-science tools designed to revolutionize biology through a relentless pursuit of scientific truth. Its core technologies are based on microfluidics and mass cytometry, and enable the exploration and analysis of individual cells, as well as the industrial application of genomics.

Most microfluidics experts in the 1990s worked with rigid substances like silicon, glass or plastic, but a young Stephen Quake, PhD, endeavored to create complex microplumbing from a novel rubber substrate. He and co-inventor Marc Unger built a microscopic valve to control the flow of fluids within microchannels—and a new approach to integrating biological liquid handling was born.

Meanwhile, Gajus Worthington, a college classmate of Quake’s, was acquiring the skills and experience necessary to build a successful company. Mentored in his early 20s by thought leaders such as Jim Collins, he set upon his personal mission to create an organization that would make lasting contributions to science and technology. In 1999 Worthington and Quake united the possibilities of Quake’s breakthrough with the desire to enable ever greater biological discoveries and co-founded Fluidigm. Today the company’s integrated fluidic circuits(IFCs) offer rapid, efficient, highly parallel and reproducible analysis of up to hundreds of genetic markers across thousands of DNA samples in just hours, rather than days or weeks, all the way down to the level of the individual cell.

The Fluidigm microfluidic technology supports genomics-based applications such as single-cell gene expression, high-throughput SNP genotyping, protein expression analysis, digital PCR, mutant detection and more. Additionally, two of the company’s instruments have proven to be workhorses within the life science industry: the Biomark™ HD and C1™ systems.

Originally introduced in 2006 and updated in 2011, Biomark HD stands alone in the world of analytical instrumentation as a multiapplication platform without compromise, providing high quality results for every experimental approach. Since its debut in 2012, the C1 system has been revolutionizing single-cell research by enabling researchers to rapidly and reliably isolate, process and profile individual cells for genomic analysis.

C1 researchers study cell differentiation, measure individual cell responses to specific stimuli, verify critical disease biomarkers, validate RNAi knockdown and conduct candidate drug screens. Select BioSciences, an independent research company, said in its January 2011 report on Single Cell Analysis (SCA) that “Fluidigm is the leading microfluidics company for SCA…[and] Fluidigm is well-positioned to become a leader in SCA.”

By 2013 the company’s position in the single-cell movement was clear: Independent research firm DeciBio in its August report entitled Single Cell Genomics (SCG): Market Size, Segmentation, Growth, Competition and Trends identified Fluidigm as the “undisputed leader in single-cell genomics.”

In 2014 Fluidigm expanded into single-cell proteomics with its acquisition of technology leader DVS Sciences, the inventor of CyTOF®, a multi-parameter single-cell protein analysis system. The CyTOF 2 mass cytometer analyzes antibody and metal complexes using an innovative method of atomic mass spectrometry, and solidifies Fluidigm’s position at the leading edge of single-cell biology.

Today more than 400 people work for Fluidigm worldwide. The company works with more than 1,000 valued customers pioneering the field of single-cell biology or using applied genomics in industrial applications to improve and protect our food supplies, track samples in the world's largest biobanks and in general provide faster, more accurate, lower cost workflows to help improve people's lives.

Fluidigm is headquartered in South San Francisco, California, with sales and sales support operations from Beijing to Tokyo to Paris to San Francisco. Fluidigm conducts its Research and Development activities and manufactures its instruments, integrated fluidic circuits and reagents in its factories in South San Francisco, Singapore and Markham, Ontario.

上海金畔生物科技有限公司